206 related articles for article (PubMed ID: 23704555)
1. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Veeraraghavalu K; Zhang C; Miller S; Hefendehl JK; Rajapaksha TW; Ulrich J; Jucker M; Holtzman DM; Tanzi RE; Vassar R; Sisodia SS
Science; 2013 May; 340(6135):924-f. PubMed ID: 23704555
[TBL] [Abstract][Full Text] [Related]
2. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Tesseur I; Lo AC; Roberfroid A; Dietvorst S; Van Broeck B; Borgers M; Gijsen H; Moechars D; Mercken M; Kemp J; D'Hooge R; De Strooper B
Science; 2013 May; 340(6135):924-e. PubMed ID: 23704554
[TBL] [Abstract][Full Text] [Related]
3. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Price AR; Xu G; Siemienski ZB; Smithson LA; Borchelt DR; Golde TE; Felsenstein KM
Science; 2013 May; 340(6135):924-d. PubMed ID: 23704553
[TBL] [Abstract][Full Text] [Related]
4. Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Fitz NF; Cronican AA; Lefterov I; Koldamova R
Science; 2013 May; 340(6135):924-c. PubMed ID: 23704552
[TBL] [Abstract][Full Text] [Related]
5. Response to comments on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models".
Landreth GE; Cramer PE; Lakner MM; Cirrito JR; Wesson DW; Brunden KR; Wilson DA
Science; 2013 May; 340(6135):924-g. PubMed ID: 23704556
[TBL] [Abstract][Full Text] [Related]
6. ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models.
Cramer PE; Cirrito JR; Wesson DW; Lee CY; Karlo JC; Zinn AE; Casali BT; Restivo JL; Goebel WD; James MJ; Brunden KR; Wilson DA; Landreth GE
Science; 2012 Mar; 335(6075):1503-6. PubMed ID: 22323736
[TBL] [Abstract][Full Text] [Related]
7. ABCA1 is Necessary for Bexarotene-Mediated Clearance of Soluble Amyloid Beta from the Hippocampus of APP/PS1 Mice.
Corona AW; Kodoma N; Casali BT; Landreth GE
J Neuroimmune Pharmacol; 2016 Mar; 11(1):61-72. PubMed ID: 26175148
[TBL] [Abstract][Full Text] [Related]
8. Medicine. Old drug, new hope for Alzheimer's disease.
Strittmatter WJ
Science; 2012 Mar; 335(6075):1447-8. PubMed ID: 22442467
[No Abstract] [Full Text] [Related]
9. Possible Molecular Interactions of Bexarotene - A Retinoid Drug and Alzheimer's Aβ Peptide: A Docking Study.
Mirza Z; Beg MA
Curr Alzheimer Res; 2017; 14(3):327-334. PubMed ID: 27842487
[TBL] [Abstract][Full Text] [Related]
10. Preclinical success against Alzheimer's disease with an old drug.
LaFerla FM
N Engl J Med; 2012 Aug; 367(6):570-2. PubMed ID: 22873540
[No Abstract] [Full Text] [Related]
11. Early Treatment Critical: Bexarotene Reduces Amyloid-Beta Burden In Silico.
Rosenthal J; Belfort G; Isaacson D
PLoS One; 2016; 11(4):e0153150. PubMed ID: 27073866
[TBL] [Abstract][Full Text] [Related]
12. Clearing Amyloid-β through PPARγ/ApoE Activation by Genistein is a Treatment of Experimental Alzheimer's Disease.
Bonet-Costa V; Herranz-Pérez V; Blanco-Gandía M; Mas-Bargues C; Inglés M; Garcia-Tarraga P; Rodriguez-Arias M; Miñarro J; Borras C; Garcia-Verdugo JM; Viña J
J Alzheimers Dis; 2016; 51(3):701-11. PubMed ID: 26890773
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene Promotes Cholesterol Efflux and Restricts Apical-to-Basolateral Transport of Amyloid-β Peptides in an In Vitro Model of the Human Blood-Brain Barrier.
Kuntz M; Candela P; Saint-Pol J; Lamartinière Y; Boucau MC; Sevin E; Fenart L; Gosselet F
J Alzheimers Dis; 2015; 48(3):849-62. PubMed ID: 26402114
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer's disease.
Cummings JL; Zhong K; Kinney JW; Heaney C; Moll-Tudla J; Joshi A; Pontecorvo M; Devous M; Tang A; Bena J
Alzheimers Res Ther; 2016 Jan; 8():4. PubMed ID: 26822146
[TBL] [Abstract][Full Text] [Related]
15. Neuronally-directed effects of RXR activation in a mouse model of Alzheimer's disease.
Mariani MM; Malm T; Lamb R; Jay TR; Neilson L; Casali B; Medarametla L; Landreth GE
Sci Rep; 2017 Feb; 7():42270. PubMed ID: 28205585
[TBL] [Abstract][Full Text] [Related]
16. RNA-sequencing reveals transcriptional up-regulation of Trem2 in response to bexarotene treatment.
Lefterov I; Schug J; Mounier A; Nam KN; Fitz NF; Koldamova R
Neurobiol Dis; 2015 Oct; 82():132-140. PubMed ID: 26071899
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 Fatty Acids Augment the Actions of Nuclear Receptor Agonists in a Mouse Model of Alzheimer's Disease.
Casali BT; Corona AW; Mariani MM; Karlo JC; Ghosal K; Landreth GE
J Neurosci; 2015 Jun; 35(24):9173-81. PubMed ID: 26085639
[TBL] [Abstract][Full Text] [Related]
18. Treatment with bexarotene, a compound that increases apolipoprotein-E, provides no cognitive benefit in mutant APP/PS1 mice.
LaClair KD; Manaye KF; Lee DL; Allard JS; Savonenko AV; Troncoso JC; Wong PC
Mol Neurodegener; 2013 Jun; 8():18. PubMed ID: 23764200
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of the retinoid X receptor facilitates beta-amyloid clearance across the blood-brain barrier.
Bachmeier C; Beaulieu-Abdelahad D; Crawford F; Mullan M; Paris D
J Mol Neurosci; 2013 Feb; 49(2):270-6. PubMed ID: 22890420
[TBL] [Abstract][Full Text] [Related]
20. ApoE: the link between Alzheimer's-related glucose hypometabolism and Aβ deposition?
Patil SP; Ballard R; Sanchez S; Osborn J; Santangelo D
Med Hypotheses; 2012 Apr; 78(4):494-6. PubMed ID: 22285195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
